Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 3, 2006, Pages 319-325

  Fruscio, Robert ^a,b   Lissoni, Andrea A ^a   Frapolli, Roberta ^b   Corso, Silvia ^a   Mangioni, Costantino ^a   D'Incalci, Maurizio ^b   Zucchetti, Massimo ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

1 acid glycoprotein; Clindamycin; Ovarian cancer; Paclitaxel; Pharmacokinetics; Protein binding

Indexed keywords

ACUTE PHASE PROTEIN; ANTINEOPLASTIC AGENT; CLINDAMYCIN; OROSOMUCOID; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG UPTAKE; FEMALE; HUMAN; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TISSUE DISTRIBUTION;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINDAMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; OROSOMUCOID; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN BINDING;

EID: 33744489070     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0160-y     Document Type: Article

References (17)

1. Chan S, Gerson B (1987) Free drug monitoring. Clin Lab Med 7:279-287
2. Barre J, Didey F, Delion F, Tillement JP (1988) Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit 10:133-143
3. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454-1457
4. Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A (2002) Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20:574-581
5. Kuvibidila S, Warrier RP, Yu L, Ode D, Mbele V (1994) Reference levels of acute phase reactant proteins in healthy Zairean women in the reproductive age group. J Trop Med Hyg 97:239-243
6. Piver MS, Moyer M, Diakun K, Lele SB, Chu TM (1988) Serum alpha 1-acid glycoprotein in epithelial ovarian cancer. Gynecol Oncol 29:305-308
7. Elg SA, Mayer AR, Carson LF, Twiggs LB, Hill RB, Ramakrishnan S (1997) Alpha-1 acid glycoprotein is an immunosuppressive factor found in ascites from ovarian carcinoma. Cancer 80:1448-1456
8. Harshman S, Reynolds VH, Neumaster T, Patikas T, Worrall T (1974) The prognostic significance of serial seromucoid analyses in patients with cancer. Cancer 34:291-299
9. Fish RG, Yap AK, James K (1982) Changes in serum acute phase proteins in breast cancer patients receiving methotrexate infusion therapy. Clin Biochem 15:4-8
10. Fish RG, Gill TS, Adams M, Faqeera F, Kerby I (1984) Changes in serum acute phase proteins in ovarian cancer patients receiving cis- diamminedichloroplatinum (CDDP) infusion therapy. Clin Biochem 17:39-41
11. Ganz PA, Baras M, Ma PY, Elashoff RM (1984) Monitoring the therapy of lung cancer with alpha-1-acid glycoprotein. Cancer Res 44:5415-5421
12. Kremer JM, Wilting J, Janssen LH (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40:1-47
13. Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D'Incalci M (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92:1641-1650
14. Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G, D'Incalci M (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9:625-632
15. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58:3248-3253
16. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24:153-172
17. Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC (1989) Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother 33(5):618-620